Since SGLT2i and GLP-1 RA exhibit cardiovascular, renal, and weight-reduction benefits independent of their blood-glucose-lowering effect (10), recent diabetes guidelines recommend using these medication classes for T2DM patients with established ASCVD, HF, or CKD, or for those at high risk of ASCVD (11, 12). This evidence concerns the gene GLP1R and atherosclerosis.